Angela Fowler-Brown, MD; Michael Pignone, MD, MPH; Mark Pletcher, MD, MPH; Jeffrey A. Tice, MD; Sonya F. Sutton, BSPH; Kathleen N. Lohr, PhD
Acknowledgments: The authors thank Jacqueline Besteman, JD, Director of the Agency for Healthcare Research and Quality EPC Programs; David Atkins, MD, MPH, Chief Medical Officer of the Agency for Healthcare Research and Quality Center for Practice Technology and Assessment; Jean Slutsky, PA, MSPH, Agency for Healthcare Research and Quality Task Order Officer, for their assistance. They also thank Paul Frame, MD, Tri-County Family Medicine, Cohocton, New York, and Carolyn Westhoff, MD, MPH, Department of Obstetrics and Gynecology, Columbia University, New York, New York, who were the liaisons for the U.S. Preventive Services Task Force. Finally, they thank Tammeka Swinson, BA, and Loraine Monroe of RTI International.
Grant Support: By contract 290-97-0011, Task Order 3, from the U.S. Preventive Services Task Force, Agency for Healthcare Research and Quality.
Potential Financial Conflicts of Interest:Consultancies: M. Pignone (Bayer, Inc.); Honoraria: M. Pignone (Bayer, Inc.); Expert testimony: M. Pignone (Bayer, Inc.); Grants received: M. Pignone (Bayer, Inc.); Royalties: M. Pignone (Bayer, Inc.).
Requests for Single Reprints: Reprints are available from the Agency for Healthcare Research and Quality Web site (www.preventiveservices.ahrq.gov) and through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295).
Current Author Addresses: Drs. Fowler-Brown and Pignone: Division of General Internal Medicine, University of North Carolina at Chapel Hill, 5039 Old Clinic Building, UNC Hospital, Chapel Hill, NC 27599-7110.
Dr. Pletcher: Department of Epidemiology and Biostatistics, University of California, San Francisco, 500 Parnassus Avenue, MU 420 W, San Francisco, CA 94143-0560.
Dr. Tice: Division of General Internal Medicine, University of California, San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143.
Ms. Sutton and Dr. Lohr: RTI International, 3040 Cornwallis Road, P.O. Box 21294, Research Triangle Park, NC 27709.
Coronary heart disease is the leading cause of morbidity and mortality in the United States. Exercise tolerance testing has been proposed as a means of better identifying asymptomatic patients at high risk for coronary heart disease events.
To review the evidence on the use of exercise tolerance testing to screen adults with no history of cardiovascular disease for coronary heart disease.
The MEDLINE database from 1966 through February 2003, hand-searching of bibliographies, and expert input.
Eligible studies evaluated the benefits or harms of exercise tolerance testing when added to traditional risk assessment for adults with no known history of cardiovascular events.
One reviewer extracted information from eligible articles into evidence tables, and another reviewer checked the tables. Disagreements were resolved by consensus.
No study has directly examined the effect of screening asymptomatic patients with exercise tolerance testing on coronary heart disease outcomes or risk-reducing behaviors or therapies. Multiple cohort studies demonstrate that screening exercise tolerance testing identifies a small proportion of asymptomatic persons (up to 2.7% of those screened) with severe coronary artery obstruction who may benefit from revascularization. Several large prospective cohort studies, conducted principally in middle-aged men, suggest that exercise tolerance testing can provide independent prognostic information about the risk for future coronary heart disease events (relative risk with abnormal exercise tolerance testing, 2.0 to 5.0). However, when the risk for coronary heart disease events is low, most positive findings will be false and may result in unnecessary further testing or worry. The risk level at which the benefits of additional prognostic information outweigh the harms of false-positive results is unclear and requires further study.
Although screening exercise tolerance testing detects severe coronary artery obstruction in a small proportion of persons screened and can provide independent prognostic information about the risk for coronary heart disease events, the effect of this information on clinical management and disease outcomes in asymptomatic patients is unclear.
Table 1. Excluded Studies
Table 2. Studies of the Use of Exercise Electrocardiography To Detect Asymptomatic Prevalent Coronary Heart Disease
Table 3. Association between Abnormal ST-Segment Response to Exercise and Coronary Heart Disease Events in Asymptomatic Persons
Table 4. Association between Exercise Predictors and Coronary Heart Disease Events in Asymptomatic Persons
Fowler-Brown A, Pignone M, Pletcher M, et al. Exercise Tolerance Testing To Screen for Coronary Heart Disease: A Systematic Review for the Technical Support for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:W–9–W–24. doi: https://doi.org/10.7326/0003-4819-140-7-200404060-w1
Download citation file:
Published: Ann Intern Med. 2004;140(7):W-9-W-24.
Cardiology, Coronary Heart Disease, Guidelines.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use